First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

BACKGROUND: ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro activity against crizotinib-resistant ALK-positive tumors. This open-label, multicenter, first-in-human phase I study (NCT01284192) assessed the safety, pharmacokinetic profile, and antitum...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tianhong, LoRusso, Patricia, Maitland, Michael L., Ou, Sai-Hong Ignatius, Bahceci, Erkut, Ball, Howard A., Park, Jung Wook, Yuen, Geoffrey, Tolcher, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786998/
https://www.ncbi.nlm.nih.gov/pubmed/26966027
http://dx.doi.org/10.1186/s13045-016-0254-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786998/
https://www.ncbi.nlm.nih.gov/pubmed/26966027
http://dx.doi.org/10.1186/s13045-016-0254-5

Ejemplares similares